Consequently, it is believed that the loss of p16ink4a is a key hallmark of RAS driven tumors and is frequently observed in a host of tumors with deregulation of the KRAS/RAF oncogenic singnaling pathway including non-small cell lung cancer, melanoma and colorectal cancer, in addition to PDA [18-20]. Here, KRAS is linked to Patent ductus arteriosus.